Salisbury Foundation Trust

FOI_4760

Internal Reference Number: FOI_4760

Date Request Received: 05/12/2018 16:09:25

Date Request Replied To: 21/01/2019 09:36:56

This response was sent via: By Email

Request Summary: Cancer treatments

Request Category: Private Individuals






 
Question Number 1:
Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care
 
Answer To Question 1:
39 patients received total of 71 treatments from 1st June 2018 - 1st December 2018.
 
Question Number 2:
Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

disodium pamidronate (Aredia)
ibandronic acid or ibandronate (Bondronat)
sodium clodronate (Bonefos, Clasteon, Loron)
zoledronic acid or zoledronate (Zometa)
denosumab (Xgeva)
 
Answer To Question 2:
The following numbers of patients were treated
in the interval of interest:

Ibandronate 3
Sodium clodronate 0

The other drugs are issued as stock to clinics, therefore
pharmacy cannot determine patient numbers
Quantities issued were as follows

Pamidronate 15mg pack 4 Q= 2
30mg pack 2 90
60mg pack 1 4
90mg pack 1 16
Zoledonate 4mg/5ml 652
Denosumab 60mg 35
120mg 264
 
Question Number 3:
Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;

disodium pamidronate (Aredia)
ibandronic acid or ibandronate (Bondronat)
sodium clodronate (Bonefos, Clasteon, Loron)
zoledronic acid or zoledronate (Zometa)
 
Answer To Question 3:
Please see answer to Question 2
 
Question Number 4:
Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
 
Answer To Question 4:
18 patients received a total of 27 treatments from 1st June 2018 - 1st December 2018.
 
Question Number 5:
Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

disodium pamidronate (Aredia)
ibandronic acid or ibandronate (Bondronat)
sodium clodronate (Bonefos, Clasteon, Loron)
zoledronic acid or zoledronate (Zometa)
denosumab (Xgeva)
 
Answer To Question 5:
Please see answer to Question 2
 
Question Number 6:
Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.
 
Answer To Question 6:
< 5 patients received < 5 treatments from 1st June 2018 - 1st December 2018. Cannot give the exact number due to Information Governance restrictions.
 
Question Number 7:
Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

disodium pamidronate (Aredia)
ibandronic acid or ibandronate (Bondronat)
sodium clodronate (Bonefos, Clasteon, Loron)
zoledronic acid or zoledronate (Zometa)
denosumab (Xgeva)
 
Answer To Question 7:
Please see answer to Question 2
Please see attachments:
RE 4760 FOI Request (1).msg
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values